Patents by Inventor Stuart Maxwell Pitson

Stuart Maxwell Pitson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10583115
    Abstract: The present disclosure relates to modulators of 14-3-3 functionality and their use in methods and compositions for preventing and/or treating various diseases, conditions and states, such as cancer and healing of wounds. Certain embodiments of the present disclosure provide a method of preventing and/or treating a disease, condition or state in a subject associated with altered 14-3-3 protein functionality and/or which would benefit from altering 14-3-3 functionality, the method comprising administering to the subject an effective amount of an agent which inhibits dimerization of the 14-3-3 protein, thereby preventing and/or treating the disease, condition or state in the subject.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: March 10, 2020
    Assignees: University of South Australia, Central Adelaide Local Health Network Inc.
    Inventors: Joanna Woodcock, Angel Lopez, Stuart Maxwell Pitson, Michael Susithiran Samuel, Carl Coolen
  • Patent number: 9828351
    Abstract: The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: November 28, 2017
    Assignees: MONASH UNIVERSITY, UNIVERSITY OF SOUTH AUSTRALIA, CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED
    Inventors: Bernard Luke Flynn, Luigi Aurelio, Carmen Vittoria Scullino, Bing Hui Wang, Stuart Maxwell Pitson, Melissa Rose Pitman
  • Publication number: 20170312249
    Abstract: The present disclosure relates to modulators of 14-3-3 functionality and their use in methods and compositions for preventing and/or treating various diseases, conditions and states, such as cancer and healing of wounds. Certain embodiments of the present disclosure provide a method of preventing and/or treating a disease, condition or state in a subject associated with altered 14-3-3 protein functionality and/or which would benefit from altering 14-3-3 functionality, the method comprising administering to the subject an effective amount of an agent which inhibits dimerization of the 14-3-3 protein, thereby preventing and/or treating the disease, condition or state in the subject.
    Type: Application
    Filed: October 8, 2015
    Publication date: November 2, 2017
    Applicants: University of South Australia, Central Adelaide Local Health Network Inc.
    Inventors: Joanna Woodcock, Angel Lopez, Stuart Maxwell Pitson, Michael Susithiran Samuel, Carl Coolen
  • Publication number: 20170190698
    Abstract: The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.
    Type: Application
    Filed: June 26, 2015
    Publication date: July 6, 2017
    Inventors: Bernard Luke Flynn, Luigi Aurelio, Carmen Vittoria Scullino, Bing Hui Wang, Stuart Maxwell Pitson, Melissa Rose Pitman
  • Patent number: 7112427
    Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: September 26, 2006
    Assignee: Johnson & Johnson Pharmaceutical Research and Development LLC
    Inventors: Stuart Maxwell Pitson, Brian Wolff Wattenberg, Pu Xia, Richard James D'Andrea, Jennifer Ruth Gamble, Matthew Alexander Vadas
  • Publication number: 20040132053
    Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.
    Type: Application
    Filed: August 18, 2003
    Publication date: July 8, 2004
    Applicant: Johnson & Johnson Pharmaceutical R and D LLC
    Inventors: Stuart Maxwell Pitson, Brian Wolff Wattenberg, Pu Xia, Richard James D'Andrea, Jennifer Ruth Gamble, Matthew Alexander Vadas
  • Patent number: 6730480
    Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic application.
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: May 4, 2004
    Assignee: Johnson & Johnson Pharmaceutical Research and Development LLC
    Inventors: Stuart Maxwell Pitson, Brian Wolff Wattenberg, Pu Xia, Richard James D'Andrea, Jennifer Ruth Gamble, Matthew Alexander Vadas